Acelyrin Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 83

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $238M

Acelyrin General Information

Description

Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Contact Information

Formerly Known As
Atlan International Holdings
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4149 Liberty Canyon Road
  • Agoura Hills, CA 91301
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 4149 Liberty Canyon Road
  • Agoura Hills, CA 91301
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Acelyrin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-May-2025 $238M Completed Generating Revenue
4. IPO 05-May-2023 Completed Generating Revenue
3. Later Stage VC (Series C) 09-Sep-2022 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series B) 16-Nov-2021 $250M $258M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 09-Oct-2020 $8M $8M Completed Startup
To view Acelyrin’s complete valuation and funding history, request access »

Acelyrin Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 8,000,000 $0.000010 8% $1 $1 1x $1 6.22%
To view Acelyrin’s complete cap table history, request access »

Acelyrin Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops
Drug Discovery
Agoura Hills, CA
83 As of 2024

Newark, CA
 

Rockville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Acelyrin Competitors (71)

One of Acelyrin’s 71 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Protagonist Therapeutics Formerly VC-backed Newark, CA
NovaBridge Biosciences Formerly VC-backed Rockville, MD
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Minerva Neurosciences Formerly VC-backed Burlington, MA
Ayala Pharmaceuticals Corporation Wilmington, DE
You’re viewing 5 of 71 competitors. Get the full list »

Acelyrin Patents

Acelyrin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025244076-A1 Methods and compositions comprising lonigutamab for treating ted Pending 20-Mar-2024
WO-2025207408-A1 Methods and compositions comprising lonigutamab for treating ted Pending 20-Mar-2024
WO-2025054498-A1 Methods of treating hidradenitis suppurativa Inactive 08-Sep-2023
WO-2025054491-A1 Methods of treatment of psoriatic arthritis Inactive 08-Sep-2023
WO-2025054497-A1 Methods of treatment of uveitis Inactive 08-Sep-2023 A61P27/02
To view Acelyrin’s complete patent history, request access »

Acelyrin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acelyrin Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Access Biotechnology Corporate Venture Capital Minority
Cowen Healthcare Investments Venture Capital Minority
Decheng Capital Venture Capital Minority
General Atlantic Growth/Expansion Minority
Marshall Wace Hedge Fund Minority
You’re viewing 5 of 13 investors. Get the full list »

Acelyrin Acquisitions (1)

Acelyrin’s most recent deal was a Merger/Acquisition with ValenzaBio for . The deal was made on 04-Jan-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ValenzaBio 04-Jan-2023 Merger/Acquisition Biotechnology
To view Acelyrin’s complete acquisitions history, request access »

Acelyrin ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.21 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Acelyrin’s complete esg history, request access »

Acelyrin FAQs

  • When was Acelyrin founded?

    Acelyrin was founded in 2020.

  • Where is Acelyrin headquartered?

    Acelyrin is headquartered in Agoura Hills, CA.

  • What is the size of Acelyrin?

    Acelyrin has 83 total employees.

  • What industry is Acelyrin in?

    Acelyrin’s primary industry is Drug Discovery.

  • Is Acelyrin a private or public company?

    Acelyrin is a Private company.

  • What is the current valuation of Acelyrin?

    The current valuation of Acelyrin is .

  • What is Acelyrin’s current revenue?

    The current revenue for Acelyrin is .

  • How much funding has Acelyrin raised over time?

    Acelyrin has raised $1.1B.

  • Who are Acelyrin’s investors?

    Access Biotechnology, Cowen Healthcare Investments, Decheng Capital, General Atlantic, and Marshall Wace are 5 of 13 investors who have invested in Acelyrin.

  • Who are Acelyrin’s competitors?

    Protagonist Therapeutics, NovaBridge Biosciences, Sarepta Therapeutics, Minerva Neurosciences, and Ayala Pharmaceuticals are some of the 71 competitors of Acelyrin.

  • When was Acelyrin acquired?

    Acelyrin was acquired on 21-May-2025.

  • Who acquired Acelyrin?

    Acelyrin was acquired by Alumis (United States).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process